Neutrisci Announces Successful Completion of Phase 1 R&D Development of a Cannabinol Product ACCESSWIRE VANCOUVER, BC / ACCESSWIRE / May 10, 2021 / NeutriSci International Inc. ('NeutriSci' or the 'Company') (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce the Phase 1 R&D completion of a newly developed Cannabinol (CBN) product for the US marketplace. In conjunction with its contract manufacturing partner Pacwest, the completion of Phase 1 used NeutriSci's IP, technologies, and ingredients to create a finished CBN tablet product. CBN is known for is its 'sleepiness effect.' When taken, it is known to cause drowsiness. Sleep problems are widespread in modern society. According to the Center for Disease Control, one in three adults do not get enough sleep. Sleep-deprived individuals are more likely to suffer from the most damaging health problems of the modern world, including coronary heart disease, cancer, and arthritis.